VPH engages with regulatory and policy stakeholders at the annual RAPS Euro Convergence conference

The conference provided a platform to highlight the transformative potential of in silico methodologies in revolutionising medical product safety and performance.

A dedicated session on in silico methodologies, featured four talks making a strong pitch for computer modelling and simulation. Speakers from the in silico community presented tangible evidence, inlcuding:

• an academic insight on the landscape and the scientific advancement on in silico trials (Prof. Alex Frangi, UK-CEiRSI – University of Manchester, VPH),
• an industry perspective on the use of modelling in product testing, alongside the development of ASME V&V 40 standard (Jeff Bischoff, PhD, Zimmer Biomet),
• the clinical insights on evaluating uncertainty and next steps for leveraging in silico evidence in regulatory assessment (Dr. Gavin Quigley, BSI, Notified Body), and finally
• the economic incentives driving this adoption (Michael Kipping, PhD, Elements).

The audience actively engaged in Q&A, leading to a key takeaway on the significant de-risking and cost-reduction potential that in silico medicine technologies offer along the entire lifecycle of medical product development.

Alongside these presentations, the VPH Scientific Officer Dr. Janaki Raman Rangarajan reported on the ecosystem initiatives of the VPH and Avicenna Alliance, which are aimed at accelerating regulatory science.

RAPS Euro Convergence 2025, was a welcome opportunity to spread the word on in silico medicine to regulatory professionals and connect with the wider community.